Raymond James Financial’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.75M Buy
89,960
+79,870
+792% +$7.5M ﹤0.01% 2269
2026
Q2
$905K Sell
10,090
-476
-5% -$39.2K ﹤0.01% 4071
2026
Q1
$837K Buy
10,566
+651
+7% +$52.6K ﹤0.01% 3982
2025
Q4
$815K Buy
9,915
+1,837
+23% +$142K ﹤0.01% 3918
2025
Q3
$564K Buy
8,078
+141
+2% +$9.5K ﹤0.01% 4039
2025
Q2
$509K Sell
7,937
-1,159
-13% -$71.8K ﹤0.01% 3999
2025
Q1
$577K Sell
9,096
-9,782
-52% -$658K ﹤0.01% 3848
2024
Q4
$1.26M Buy
+18,878
New +$1.3M ﹤0.01% 3293

Other funds holding PBE

Raymond James Financial's PBE Position: Q3 2026 in Review

Raymond James Financial increased its Invesco Biotechnology & Genome ETF (PBE) stake by 792% in Q3 2026, buying an estimated $7.5M and bringing the position to 89,960 shares worth $8.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2269.

Raymond James Financial first reported a position in PBE in Q4 2024 and has held it in 8 quarters since. 123 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

  • Raymond James Financial held 89,960 shares of Invesco Biotechnology & Genome ETF worth $8.75M as of Q3 2026.
  • Raymond James Financial bought 79,870 Invesco Biotechnology & Genome ETF shares in Q3 2026, an estimated $7.5M.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #2269 holding.
  • Raymond James Financial first reported a position in Invesco Biotechnology & Genome ETF in Q4 2024 and has held it in 8 quarters since.
  • 123 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.